Clik here to view.
Masimo SpHb®による連続的・非侵襲的ヘモグロビン測定が不必要な輸血を減らすことの有用性および経済的影響を検討する新研究
マドリード （ビジネスワイヤ） — マシモ（NASDAQ: MASI）は、マシモの非侵襲的かつ連続的なヘモグロビン測定値（SpHb®）の有用性に関して最近公表された研究の知見について発表しました。この研究は、不必要な輸血を減らして、経費を削減し、医療の質を改善する上で、SpHb®の有用性を評価したものです1。...
View ArticleClik here to view.
新研究调查Masimo SpHb®连续无创血红蛋白测定在减少不必要输血方面的经济影响和功用
马德里 (美国商业资讯) — Masimo (NASDAQ: MASI)今天发布了一项近期发表的研究的结果，该研究中，研究人员评估了Masimo 无创连续血红蛋白(SpHb®)在减少不必要输血的次数、从而降低成本、提高医护品质方面的功用1。 该研究中，ETSII-西班牙国立远程教育大学(UNED) HM医院和圣保罗大学(CEU San Pablo...
View ArticleClik here to view.
Clik here to view.
继美国和英国之后，中国向Personalis, Inc.签发ACE©技术专利，扩大了其在国际上的知名度
加州门罗帕克 (美国商业资讯) — Personalis, Inc.是一家面向免疫肿瘤学的高级基因组测序和分析提供商，公司今天宣布，中国国家知识产权局已签发了ACE©技术平台的专利，专利编号为ZL 2013 8...
View ArticleClik here to view.
Cerveau Technologies, Inc.与日本东京都老人综合研究所签订研究协议
波士顿 — (美国商业资讯) — Cerveau Technologies Inc.今天宣布与日本东京都老人综合研究所(Tokyo Metropolitan Institute of...
View ArticleClik here to view.
Takeda to Highlight Broad Oncology Portfolio and Pipeline Data at the...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the company will feature a total of 14 Takeda Oncology-sponsored presentations at two...
View ArticleClik here to view.
GRAIL Announces $300 Million Raised in Oversubscribed Series C Financing
MENLO PARK, Calif. & HONG KONG GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced it has raised USD$300 million in an oversubscribed...
View ArticleClik here to view.
AVITA Medical Announces Presentation at ISPOR Meeting Validating Acute Burn...
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical (ASX: AVH, OTCQX: AVMXY) today announced that results from a study validating the predicted outcomes and costs from an acute burns health...
View ArticleClik here to view.
武田在美国临床肿瘤学会(ASCO)和欧洲血液学会(EHA)年会上重点介绍其强大的肿瘤产品阵容和后续产品线数据
马萨诸塞州剑桥和日本大阪 武田药品工业株式会社(TSE: 4502)今天宣布，将在即将召开的两次医学会议上进行14场武田肿瘤部赞助的呈报：6月1-5日在芝加哥召开的美国临床肿瘤学会(ASCO)第54届年会和6月14-17日在斯德哥尔摩召开的欧洲血液学会(EHA)第23届大会。今年的呈报将强调武田对促进血液肿瘤治疗的不懈追求，并不断推进难治性实体瘤领域的研究。 武田肿瘤部总裁Christophe...
View ArticleClik here to view.
武田薬品が米国臨床腫瘍学会（ASCO）と欧州血液学会（EHA）の年次総会でオンコロジーの広範なポートフォリオとパイプラインのデータを発表
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） — 武田薬品工業株式会社(TSE: 4502)は本日、近く開催される2件の医学学会で、Takeda...
View ArticleClik here to view.
Prota/MCRI Completes Enrolment of Phase 2b Multicentre Clinical Trial of...
MELBOURNE, Australia Pioneering allergy immunotherapy company Prota Therapeutics Pty Ltd (Prota) is pleased to announce full enrolment to the multicentre Phase 2b clinical trial investigating the...
View ArticleClik here to view.
Apogenix Provides Update on Clinical Development of Asunercept
HEIDELBERG, Germany Apogenix AG, a biopharmaceutical company developing next-generation immuno-oncology therapeutics, today provides an update on the clinical development and approval strategy of...
View ArticleClik here to view.
Otsuka and Lundbeck to Start Third Phase 3 Trial in June to Evaluate...
TOKYO & DEERFIELD, Ill. Otsuka Pharmaceutical Company, Ltd. (Otsuka) and Lundbeck announce that the two companies’ third clinical Phase 3 study of brexpiprazole in the treatment of agitation in...
View ArticleClik here to view.
珀金埃尔默收购上海光谱仪器有限公司
上海 (美国商业资讯)–珀金埃尔默（“PerkinElmer, Inc.”)是一家致力于通过创新打造更健康世界的全球领先企业，今天宣布已收购上海光谱仪器有限公司(“SSI”)。该公司位于中国上海漕河泾开发区，是中国领先的分析仪器制造商之一。...
View ArticleClik here to view.
PerkinElmer Acquires Shanghai Spectrum Instruments Co., Ltd.
SHANGHAI PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that it has acquired Shanghai Spectrum Instruments Co., Ltd. (SSI). Located at Shanghai...
View ArticleClik here to view.
Clinigen signs agreement with Nordic Pharma for aprotinin
BURTON-ON-TRENT, England Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has signed an agreement with Nordic Pharma Ltd. (‘Nordic Pharma’) to manage the...
View ArticleClik here to view.
Research Paper Co-authored by Dr. Damien Bates, Chief Medical Officer and...
TOKYO The SanBio Group (SanBio Co., Ltd. and subsidiary SanBio, Inc.), a scientific leader in regenerative medicine for neurological disorders, hereby announces that Cell Therapy for Chronic Stroke,...
View ArticleClik here to view.
Octapharma在 WFH 2018上分享新型皮下重组FVIII SubQ-8的有前景的临床前数据
瑞士拉亨 (美国商业资讯) — Octapharma今天宣布，SubQ-8临床前数据在英国格拉斯哥召开的世界血友病联盟(WFH) 2018年世界大会的一次研讨会上呈报。 SubQ-8目前正在开发中，是来自于人类细胞系的重组FVIII，用于皮下给药。SubQ-8的基础是Octapharma的人类细胞系衍生rFVIII产品simoctocog alpha结合 von...
View ArticleClik here to view.
Octapharma在世界血友病联盟2018年世界大会上呈报Nuwiq®造福血友病A患者的新数据
瑞士拉亨 (美国商业资讯) – Octapharma今天宣布，Nuwiq®造福血友病A患者的新数据在英国格拉斯哥召开的世界血友病联盟(WFH) 2018年世界大会的一次研讨会上呈报。Nuwiq® 是第四代人类细胞系衍生的重组FVIII (rFVIII)，获准用于预防和治疗所有年龄段血友病A患者的出血发作。此次研讨会名为“进一步满足临床需求：来自Nuwiq®▼（simoctocog...
View ArticleClik here to view.
China Drug Administration Approves Epclusa® (Sofosbuvir/Velpatasvir),...
FOSTER CITY, Calif. Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the China Drug Administration (CDA) has approved Epclusa® (sofosbuvir 400 mg/velpatasvir 100 mg) for the treatment of...
View Article